HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Carter-Wallace

This article was originally published in The Rose Sheet

Executive Summary

Carter-Wallace: Denies rumors of an impending acquisition offer, maintaining that "it does not know of any basis for the rumored offer," in a statement released May 19. The Arrid antiperspirant and Trojan condom manufacturer had been experiencing unusually heavy trading volume and on May 16 the issue closed at 18-1/8, a high for the past 52 weeks. The issue closed at 16, down 2-1/8 May 19, the day Carter-Wallace's statement was released. A story in the May 26 issue of Business Week reported a British packaged goods, foods and detergents company was planning to make a $24 per share bid for Carter-Wallace. At the end of 1996, Carter-Wallace rejected an initial offer by Davis Companies to purchase the firm for $18 per share as well as a second offer of $20 per share...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel